Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Context Therapeutics (Nasdaq:CNTX) granted a non-qualified stock option to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option covers 146,000 shares at an exercise price of $1.71, has a 10-year term, and vests over four years, subject to continued service.

AI-generated analysis. Not financial advice.

Key Figures

Inducement option size: 146,000 shares Option exercise price: $1.71 per share Option term: 10 years +3 more

6 metrics

Inducement option size 146,000 shares Non-qualified stock option grant to a new employee

Option exercise price $1.71 per share Equal to CNTX Nasdaq closing price on June 8, 2026 grant date

Option term 10 years Duration of the non-qualified stock option grant

Vesting period 4 years Stock options vest over four years, subject to continued service

Initial vesting tranche One-fourth of shares Vests on the first anniversary of the grant date

Remaining vesting installments 36 monthly installments Balance vests in thirty-six equal monthly installments after year one

Market Reality Check

Price: $1.7100 Vol: Volume 161,350 is well be...

low vol

$1.7100 Last Close

Volume Volume 161,350 is well below the 20-day average of 688,580, indicating muted trading interest ahead of this filing-style news. low

Technical Shares at $1.71 are trading below the 200-day MA ($1.78) and about 52.76% under the 52-week high.

Peers on Argus

CNTX fell 8.77% while closely ranked biotech peers like ACET, IGMS, IMMX, CNTB, ...

1 Down

CNTX fell 8.77% while closely ranked biotech peers like ACET, IGMS, IMMX, CNTB, and STRO each declined between about 1–2%, suggesting CNTX’s move was steeper and more stock-specific than the broader group.

Historical Context

5 past events · Latest: May 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 27	Conference & option grant	Positive	+13.3%	Jefferies conference appearance and inducement option grant to a new employee.
May 18	License amendment	Positive	-0.5%	Amended BioAtla CT-202 license into fully paid-up, non-terminable agreement.
May 06	Q1 2026 earnings	Neutral	-3.3%	Reported Q1 2026 financials, cash runway to mid-2027, and trial timelines.
Apr 08	Board-related news	Neutral	+0.8%	Neogen officer appointment highlighting a director who also serves on CNTX’s board.
Apr 02	Fast Track designation	Positive	+2.6%	FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.

Pattern Detected

Recent CNTX news often triggered directional moves, with positive regulatory or corporate updates generally seeing supportive price action, while licensing and earnings items showed mixed or contrary reactions.

Recent Company History

Over the last few months, Context Therapeutics has highlighted clinical and corporate milestones, including FDA Fast Track Designation for CTIM-76 in April 2026 and Q1 2026 results showing $54.5 million in cash expected to fund operations into mid-2027. A May license amendment for CT-202 reshaped its economics, and conference participation plus a prior inducement option grant on May 27, 2026 coincided with a 13.31% gain. Against this backdrop, today’s smaller inducement grant fits into ongoing hiring and pipeline build-out activity.

Market Pulse Summary

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant covering 146,000 shares...

Analysis

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant covering 146,000 shares at an exercise price of $1.71, vesting over four years. It follows a series of recent pipeline and licensing updates, including Fast Track status for CTIM-76 and a revised CT-202 license. Investors may focus more on upcoming clinical data and cash runway, while viewing this grant as a routine hiring and retention tool rather than a fundamental catalyst.

Key Terms

non-qualified stock option, nasdaq listing rule 5635(c)(4), exercise price

3 terms

non-qualified stock option financial

"Context has granted a non-qualified stock option award to purchase 146,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

nasdaq listing rule 5635(c)(4) regulatory

"granted ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"with an exercise price equal to the closing price of Context’s common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date (June 8, 2026) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date ($1.71 per share).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

What stock option inducement grant did Context Therapeutics (CNTX) announce on June 9, 2026?

Context Therapeutics announced a non-qualified stock option inducement grant covering 146,000 shares for a new employee. According to Context Therapeutics, the grant was made outside its 2021 plan as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new CNTX stock options granted as an inducement?

The exercise price of the new Context Therapeutics stock options is $1.71 per share. According to Context Therapeutics, this equals the closing price of CNTX common stock on the June 8, 2026 grant date as reported by Nasdaq.

How do the Context Therapeutics (CNTX) inducement stock options vest for the new employee?

The Context Therapeutics inducement stock options vest over four years, subject to continued service. According to Context Therapeutics, one-fourth of the 146,000 shares vest on the first anniversary, with the remaining shares vesting in 36 equal monthly installments thereafter.

What is the term of the Context Therapeutics CNTX inducement stock option grant?

The Context Therapeutics inducement stock option grant has a 10-year term from the June 8, 2026 grant date. According to Context Therapeutics, the option remains exercisable during this period, subject to standard conditions and the employee’s continued service for vesting.

Why did Context Therapeutics grant CNTX stock options outside its 2021 Long-Term Plan?

Context Therapeutics granted the stock options outside its 2021 Long-Term Performance Incentive Plan as a hiring inducement. According to Context Therapeutics, the non-qualified options qualify under Nasdaq Listing Rule 5635(c)(4) as a material inducement for the new employee to accept employment.